 InPharm | GSK severe asthma drug progresses to Phase III InPharm The year-long study, which involved 621 patients, found the number of clinically significant exacerbations in patients on GSK's drug – that is defined as episodes requiring oral corticosteroids or a hospital visit - was around half compared to placebo ... Experimental Asthma Drug Halves Attacks GSK asthma drug cuts symptoms 52%; ready for PhIII Drug 'could cut asthma A&E visits' |
